ReviewThe Indian journal of medical research2026
Cefepime-enmetazobactam for complicated urinary tract infections: Redefining ESBL therapy.
Review in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complicated urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL)- and AmpC β-lactamase-producing Enterobacterales are increasing in India, driving carbapenem use. Cefepime-enmetazobactam (CPM-EMT), a β-lactamase inhibitor active against class A ESBLs and with partial activity against AmpC, but is inactive against metallo-β-lactamases (MBLs). We conducted a narrative review (2018-2025) of PubMed/MEDLINE, ClinicalTrials.gov, and regulatory sources, prioritising randomised trials, surveillance, pharmacokinetic/pharmacodynamic studies, and antimicrobial stewardship programme (AMSP) guidance, with emphasis on Indian resistance trends. In the Phase 3 ALLIUM trial, CPM-EMT achieved superior overall treatment success versus piperacillin-tazobactam in patients with complicated UTI and acute pyelonephritis, including ESBL subgroups. In vitro, CPM-EMT restores cefepime activity against ESBL-producing Enterobacterales; activity against Pseudomonas aeruginosa is variable and largely cefepime-driven. Safety is similar to cefepime; the risk of neurotoxicity increases with renal impairment, supporting renal dose adjustment and prolonged infusion in augmented renal clearance. CPM-EMT is approved in the United States, European Union, and India. CPM-EMT is a carbapenem-sparing option for ESBL/AmpC complicated UTI when MBL risk is low or excluded by rapid carbapenemase testing and local epidemiology. It is not appropriate for empiric use in haemodynamically unstable ICU patients or where carbapenemase prevalence (e.g., NDM-β-lactamase, OXA-48-like, KPC) is high; mechanism-directed alternatives (e.g., ceftazidime-avibactam with or without aztreonam, cefiderocol) are preferred. Evidence gaps include paediatric dosing/safety, Indian real-world comparative outcomes, Pseudomonas-specific efficacy, and cost-effectiveness. Implementation in India should integrate rapid diagnostics, local antibiograms, and optimised dosing within AMSP pathways to preserve carbapenems without compromising outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.